EN | UA
EN | UA

Help Support

Back

NVSI-06-08 is safe and effective immunogenic booster in BBIBP-CorV recipients

NVSI-06-08 NVSI-06-08
NVSI-06-08 NVSI-06-08

What's new?

In healthy adults, heterologous prime-boost vaccination with 1 dose of NVSI-06-08 after 2 doses of BBIBP-CorV was immunogenic, tolerant, and safe.

A randomized, double-blind, controlled, phase 2 trial depicted that NVSI-06-08, a broad-spectrum synthetic COVID-19 vaccine, is effective and safe when given after two doses of BBIBP-CorV. Investigators aimed to assess NVSI-06-08 safety and immunogenicity as a heterologous booster vaccination in BBIBP-CorV receivers.

Healthy people aged 18 years or more were divided into three groups (600 participants in each group). Participants who received two doses of BBIBP-CorV 4-6, 7-9, and more than 9 months earlier were randomized 1:1 to get either NVSI-06-08 (heterologous booster) or BBIBP-CorV (homologous booster). The incidence of noxious effects was low and the overall safety profile was fairly identical between 2 booster regimens.

Both IgG antibodies and neutralizing antibodies triggered by the NVSI-06-08 booster were greater than those from the BBIBP-CorV booster against not only the SARS-CoV-2 prototype strain but also other variants of concern. As shown in Table 1, the geometric mean titer (GMT) against the Omicron variant induced by heterologous NVSI-06-08 booster was substantially greater than that induced by BBIBP-CorV.

NVSI-06-08 appears to be a safe and immunogenic booster dosage after 2 BBIBP-CorV doses and shows immunological superiority to another BBIBP-CorV homologous boost dose.

Source:

Nature Communications

Article:

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial

Authors:

Nawal Al Kaabi et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: